Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ifosfamide + doxorubicin + carboplatin
- Development stage
- Phase 2
- Lead developer
- NuGen Medical Devices
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A chemotherapy combination regimen consisting of ifosfamide, doxorubicin, and carboplatin. This combination has been studied for various cancers including nasopharyngeal carcinoma, soft-tissue sarcomas, and osteosarcoma. The regimen leverages the cytotoxic effects of all three agents, with ifosfamide acting as an alkylating agent, doxorubicin as an anthracycline that intercalates DNA, and carboplatin as a platinum-based agent that forms DNA adducts.
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on ifosfamide + doxorubicin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ifosfamide + doxorubicin + carboplatin.